Invasive Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Invasive Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major invasive candidiasis markets reached a value of US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.12% during 2024-2034.

The invasive candidiasis market has been comprehensively analyzed in IMARC's new report titled "Invasive Candidiasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Invasive candidiasis, also known as candidemia, is a severe fungal infection caused by Candida species, primarily Candida albicans. This disease occurs when Candida yeast, which is commonly present in the human body, overgrows and invades the bloodstream or various other internal organs, leading to a systemic infection. The indications of the ailment can vary but often include fever, chills, low blood pressure, rapid heartbeat, and organ-specific symptoms, such as abdominal pain or difficulty breathing. However, the presentation can be nonspecific, making early diagnosis challenging. The diagnosis of invasive candidiasis typically involves blood cultures to identify the presence of specific species in the bloodstream. Numerous other diagnostic methods include imaging studies like CT scans or ultrasounds to detect organ involvement, as well as tests to determine the susceptibility of Candida species to antifungal medications. A timely and accurate diagnosis is crucial, as this disease can lead to serious medical complications in patients.

The escalating incidences of fungal infection caused by an abnormal overgrowth of fungi in various parts of the body, particularly within the bloodstream and internal organs, are primarily driving the invasive candidiasis market. In addition to this, the rising prevalence of immunocompromised conditions, such as HIV/AIDS, organ transplantation, prolonged use of broad-spectrum antibiotics, etc., that can increase the likelihood of infection among individuals is creating a positive outlook for the market. Moreover, the widespread adoption of effective antifungal medications, including azoles, echinocandins, polyenes, etc., for treating and preventing invasive candidiasis is also propelling the market growth. These drugs work by targeting the yeast cells and disrupting their essential cellular components to curb the progression of the illness and avert further complications in patients. Apart from this, the inflating application of infection control practices in healthcare settings, alongside the development of rapid diagnostic techniques, like molecular methods and biomarker identification for timely and accurate detection of the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive therapies, such as intravenous fluids and immune-boosting agents, to enhance the body's defense mechanisms against fungal infection is expected to drive the invasive candidiasis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the invasive candidiasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for invasive candidiasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the invasive candidiasis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the invasive candidiasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the invasive candidiasis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current invasive candidiasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the invasive candidiasis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the invasive candidiasis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the invasive candidiasis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of invasive candidiasis across the seven major markets?
What is the number of prevalent cases (2018-2034) of invasive candidiasis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of invasive candidiasis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with invasive candidiasis across the seven major markets?
What is the size of the invasive candidiasis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of invasive candidiasis?
What will be the growth rate of patients across the seven major markets?

Invasive Candidiasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for invasive candidiasis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the invasive candidiasis market?
What are the key regulatory events related to the invasive candidiasis market?
What is the structure of clinical trial landscape by status related to the invasive candidiasis market?
What is the structure of clinical trial landscape by phase related to the invasive candidiasis market?
What is the structure of clinical trial landscape by route of administration related to the invasive candidiasis market?